Use of the hepatocyte growth factor mimetic ANG-3777 showed long-term improvement in kidney function in patients who underwent transplantation but had signs of possible kidney injury after transplant. “The two leading contributors to early graft failure are acute rejection and acute kidney injury (AKI) occurring during the transplantation process. While rejection can be managed utilizing immunosuppressant therapy, no therapies currently exist for [delayed graft function] DGF-associated AKI,” Jonathan S. Bromberg, MD, PhD, professor of surgery and microbiology and immunology and vice chair for research at the University of Maryland, and colleagues wrote.